Effects of Edoxaban on Platelet Aggregation

Overview

Rationale: The interaction between nonvitamin K oral anticoagulants (NOACs) and platelet aggregation is complex. The direct activated factor X inhibitors (factor Xa inhibitors) an NOAC antagonizes thrombin generation, one of most important platelet agonist, so that, factor Xa inhibitors has a potential effect in decreasing thrombin-mediated platelet aggregation. On the other hand, patients who experience ACS continue to have a hypercoagulable state for long periods after the index event. The COMPASS trial showed that, in patients with stable coronary artery disease (SCAD), Rivaroxaban (a direct anti-Xa inhibitor) in addition to antiplatelet agent, compared to antiplatelet therapy alone, reduced the composite endpoint of myocardial infarction, stroke and death. Objective: Analyze the role of edoxaban on platelet aggregation in SCAD patients. Methods and Results: This is a prospective, non-randomized, interventional study of SCAD patients taking low-dose acetylsalicylic acid (ASA). Subjects initially will receive in the following sequence: ASA 100 mg once daily (QD) plus edoxaban 60 mg QD, clopidogrel 75 mg QD alone, clopidogrel 75 mg QD plus edoxaban 60 mg QD, and edoxaban 60 mg QD alone. Platelet function will be assessed by standard of care technology, at baseline and after each intervention phase, by Multiplate-ADP® (primary endpoint), Multiplate-Aspi® and Multiplate-TRAP®. In addition to immature platelets fraction (% IPF) and count (IPC). Coagulability will be assessed, at baseline and after each intervention phase, by thromboelastogram (TEG) assessment. Specifically, after the phases in which edoxaban will be administered activated factor X (FXa) level and Plasminogen activator inhibitor-1 (PAI-1) will be evaluated in addition to previous. Finally, inflammatory markers will be, at same way, assessed at baseline and after intervention each phase: ultrasensitive C-reactive protein (us-PCR). Keywords: edoxaban, direct factor Xa inhibitor, stable coronary artery disease, aspirin, clopidogrel, platelet aggregation.

1\. Introduction: Stable coronary artery disease (SCAD) is the leading cause of deaths attributable to cardiovascular disease in the United States. 720,000 new coronary events are expected - defined as the first acute myocardial infarction (AMI) hospitalized or death from SCAD - and approximately 335,000 recurring events per year. Patients who survive the initial phase of acute coronary syndrome (ACS) remain at risk of cardiac complications: sudden death, (re) infarction or recurrent rest angina, complications related to the development of coronary thrombosis. The most common cause of coronary thrombosis is plaque rupture followed by plaque erosion. The plaque rupture represents a stimulus for both thrombosis and coagulation, because thrombin activates platelets and converts fibrinogen into fibrin, characteristic of the "white" arterial thrombus. Therefore, the process of arterial thrombus generation involves both platelet aggregation and blood coagulation. The importance of the coagulation system underlying plaque complications was addressed by Ardissino et al. in the Global Use of Strategies To Open ocluded coronary artteries (GUSTO) IIb, a prospective multicenter cohort study that evaluated the importance of persistently elevated thrombin generation for outcome in 319 consecutive patients with ACS. In this study, the authors concluded that after an episode of ACS, thrombin generation levels were significantly correlated with a worse U-shaped result. Orbe et al. showed that patients with a previous history of ACS being treated with platelet antiaggregants generated a higher amount of thrombin, earlier and faster, when compared to stable patients. Their results suggest that these patients could benefit from more potent antithrombotic/anticoagulant agents to prevent thrombin activation and generation. Different anticoagulant drugs have been studied for secondary prevention after ACS to reduce mortality and recurrence of ischemic events. Directly activated X factor inhibitors (factor Xa inhibitors) antagonize thrombin generation. Two representatives of this class (rivaroxaban and apixaban) were evaluated in the context of ACS: Atlas ACS-2, a phase III trial, was designed to evaluate the effect of low-dose rivaroxaban (2.5-5 mg twice daily), versus placebo in 15,526 patients with recent ACS. The primary outcome composed of cardiovascular death, AMI or stroke was significantly reduced with both doses compared to placebo (8.9% vs. 10.7%, HR 0.84 P = 0.008). Major hemorrhagic events were higher with rivaroxaban in both doses when compared with placebo (2.1% vs. 0.6%, P \<0.001); there were fewer fatal hemorrhagic events with the lowest dose of rivaroxaban compared to the highest dose (0.1% vs. 0.4%, respectively, P = 0.04). APPRAISE-2 was a randomized, double-blind, placebo-controlled phase III study that compared apixaban (5 mg twice daily) with placebo, in addition to standard antiplatelet therapy, in patients with recent ACS. It was discontinued prematurely after recruiting 7,392 patients because major bleeding events were significantly greater in the apixaban group (1.3% apixaban vs. 0.5% control, HR 2.59; P = 0.001) in the absence of a counterbalance reduction in recurrent ischemic events: primary endpoint (cardiovascular death, AMI, or ischemic stroke) 7.5% event rate in the apixaban v group. 7.9% in the placebo group, HR 0.95; P = 0.51. In patients with SCAD, the phase III COMPASS study involved 27,395 subjects randomized to receive rivaroxaban 2.5 mg twice daily plus aspirin (ASA) 100 mg once daily, rivaroxaban 5 mg twice daily, or ASA 100 mg once a day. The incidence of the primary composite endpoint of cardiac death, stroke, or AMI was significantly lower in the rivaroxaban plus aspirin group compared to the aspirin-only group (4.1 versus 5.4%; HR = 0.76; P \<0.001). On the other hand, major bleeding events were significantly higher in the rivaroxaban plus aspirin group compared to the aspirin only group (HR 1.7; P \< 0.001), but intracranial and fatal bleeding events were similar in both groups. In patients with an indication for anticoagulation after an ACS episode (e.g. patients with atrial fibrillation), guidelines recommend the use of triple antithrombotic therapy (double antiplatelet in addition to anticoagulant) initially, followed by dual antithrombotic therapy for 1 month to one year, and after 1 year only keep the anticoagulant. However, in cases of very high ischemic risk, especially if there is a low hemorrhagic risk, some choose to keep the antiplatelet drug at the same time and the antiplatelet drug can be maintain. Therefore, the demonstration of antiplatelet activity in a factor Xa inhibitor would be useful, in order to reinforce its use in isolation after the first year of the acute episode, even in patients with high ischemic risk. It has been shown in vitro that edoxaban, a direct factor Xa inhibitor, is a potent inhibitor of tissue factor-induced platelet aggregation, and its use has increased the antiplatelet effects of clopidogrel and aspirin. Despite this in vitro demonstration, there are no in vivo studies analyzing the action of this drug on platelet reactivity. The present project was designed to provide information on this important issue, analyzing the role of edoxaban on platelet aggregation in patients with SCAD or a history of AMI for more than 12 months. 2.1 Primary objective: To compare platelet aggregability in patients with SCAD using the Multiplate-TRAP® method at the start of ASA use and after 10 ± 2 days of the association of edoxaban and ASA. 2.2 Secondary objective: Comparison of platelet aggregability in different scenarios: 1.1.1 Measured by Multiplate-ADP®, Multiplate-Aspi® at baseline and after 10 ± 2 days of edoxaban and ASA. 1.1.2 Measured by Multiplate-ADP®, Multiplate-Aspi® and Multiplate-TRAP® before and after 10 ± 2 days of edoxaban and clopidogrel compared to clopidogrel alone; 1.1.3 Measured by Multiplate-ADP®, Multiplate-Aspi® and Multiplate-TRAP® before and after 10 ± 2 days of edoxaban only compared to AAS only; 1.1.4 Measured by Multiplate-ADP®, Multiplate-Aspi® and Multiplate-TRAP® before and after 10 ± 2 days of edoxaban only compared to clopidogrel alone; 1.1.5 Measured by Multiplate-ADP®, Multiplate-Aspi® and Multiplate-TRAP® before and after 10 ± 2 days of edoxaban plus clopidogrel compared to 10 ± 2 days of edoxaban and AAS. 2.3 Other secondary goals: 1.1.6 Dosage of the following parameters: 1. Total immature platelets (IPC) and fractions (%IPF), and inflammatory markers: ultrasensitive CRP after each intervention phase. 2. Thromboelastography (TEG) after each intervention phase. 3. Dosing of plasminogen activator inhibitor type 1 (PAI-1) and factor Xa activity after each intervention phase in which edoxaban is administered. 4. Analyze the primary objective of the study in the following subgroups: * Gender (male/female); * Diabetes (presence or not); * Current or not smoking; * Elderly (≥ 65 years old) and non-elderly. 3\. Methods: 3.1. Study design: Prospective, open, intervention, non-randomized study that will be conducted at Heart Institute (InCor) HCFMUSP. After signing the free and informed consent form , the patient will undergo a physical examination and be classified by the HAS-BLED according to the risk of bleeding; then, blood samples will be collected for safety assessment (complete blood count, coagulation, kidney and liver function tests). Eligible patients for the study will be evaluated at five more visits in addition to the screening visit. In four of the remaining visits there will be different interventions (first visit, second visit, third visit and fourth visit). The following laboratory tests will be performed at the beginning and after each intervention phase: Multiplate-ADP®, Multiplate-Aspi®, Multiplate-TRAP®, IPF and IPC; Ultrasensitive PCR and TEG. Specifically, after the phases in which edoxaban will be administered, FXa and PAI-1 level activity will be further evaluated. 3.2. Study procedures: During the intervention phases, eligible patients will sequentially receive ASA 100 mg 1x/day + edoxaban 60 mg 1x/day for a period of 10 ± 2 days. Subsequently, ASA and edoxaban will be suspended and clopidogrel 75 mg once a day will be administered for 10 ± 2 days (washout period of the ASA). Subsequently, it will be associated with edoxaban 60 mg once a day to clopidogrel 75 mg once a day for 10 ± 2 days and, finally, only edoxaban 60 mg once a day for 10 ± 2 days will be administered. After the end of the interventions, the ASA 100 mg once a day will be restarted. All study medications and procedures will be fully paid for by those responsible for the study, without any burden to the Unified Health System or to Supplementary Health. Criteria for stopping current medication: The study drug should be discontinued in the event of major bleeding, defined by the presence of at least one of the following criteria: fall in hemoglobin level greater than or equal to 2.0g/dL or transfusion of two or more units of packed red blood cells; bleeding from a critical site or organ such as intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal; or fatal hemorrhage. Bleeding that does not meet the criteria for major bleeding, but that has been associated with a medical intervention, an unscheduled contact (visit) with a physician, or associated with discomfort for the subject, such as pain or impairment of activities of daily living will be considered clinically relevant, but not severe bleeding. 3.3. Selection: The patients included will be selected from the outpatient clinics of the Heart Institute (InCor) HCFMUSP and from the database of the Thematic project "Platelet aggregation and antiaggregation in patients with coronary artery disease" (SDC 4086 /14/066; FAPESP 2014/01021-4) of the InCor Acute Coronary Disease Unit. 3.4. Inclusion criteria: 1. Patients aged between 18 and 75 years 2. Confirmed diagnosis of CAD using ASA 100 mg once a day. The following will be considered for SCAD diagnosis: previous history of type 1 AMI (at least one year ago), according to the fourth universal definition of myocardial infarction and/or coronary angioplasty and/or coronary artery bypass graft surgery myocardium and/or coronary angiography showing at least 50% obstruction in one of the main epicardial vessels. 3. Agreement to sign the free and informed consent form. 3.5. Exclusion criteria: * Clinically active bleeding or clinically significant bleeding in the last year. * Peptic ulcer active in the last 60 days * Previous history of high gastrointestinal bleeding * Hemoglobin \<10 g / dl at randomization; * Platelets \<100,000 or \>500,000 µ/L * Need for lumbar puncture * Atrial fibrillation * Metal valve prosthesis * Percutaneous coronary intervention (PCI) in the last 3 months with conventional stent and in the last 6 months with drug-eluting stent. * Surgical myocardial revascularization (CABG) in the last 90 days * Percutaneous coronary intervention (PCI) or surgical myocardial revascularization (CABG) planned within the next 60 days; * Previous hemorrhagic stroke; * Moderate or severe liver failure associated with coagulation disorders (Child-Pugh B or C) * Hypersensitivity to edoxaban or formula components; * Pregnant women or women of childbearing potential; * Chronic kidney disease: glomerular filtration rate estimated at \<50 mL/min/1.73m², calculated using the Cockcroft-Gault equation; * Current or last 30 days use of anticoagulant or antiplatelet therapy, except ASA; * Weight \<60 kg; * HAS-BLED score ≥ 3 points; * Concomitant use of P-glycoprotein inhibitors such as azithromycin, clarithromycin, erythromycin, itraconazole, ketoconazole, verapamil, quinidine, except amiodarone; * Concomitant use of P-glycoprotein inducers, such as Rifampicin; * Known abuse of alcohol, drugs, or medications in the 12 months prior to consent for this study; * Cancer therapy 5 years prior to consent for this study; * Medicines that will further increase the risk of bleeding (such as nonsteroidal anti-inflammatory drugs). * Participation in another study within 30 days of signing the consent form. 3.6. Procedures Blood samples: All blood samples will be collected between 8:00 am and 12:00 pm (2 to 4 hours after the last drug ingestion), after 30 minutes of rest, by antecubital venipuncture with a 21-gauge needle. Within 2 hours after collection, platelet function tests (Multiplate®) will be performed. The other samples will be centrifuged at 3,000 rpm, stored in aliquots and subsequently frozen at -80 degrees Celsius for further analysis by enzyme immunoassay (ELISA). Description of laboratory tests: 1. Multiple electrode aggregometry - MEA (Multiplate® from Roche): a volume of 3.0 ml of blood will be collected in a hirudin tube, 300 µL of this sample is diluted with 300 µL of 0.9% NaCl and incubated in a test cuvette at 37°C for 3 minutes. Then, as recommended by the manufacturer, platelet aggregation will be induced by the addition of arachidonic acid (ASPItest), ADP (ADPtest) or TRAP-6 (TRAPtest). The platelet aggregation response will be continuously recorded for 6 minutes. The increase in impedance due to the fixation of platelets to the electrodes is detected for each sensor unit separately and transformed into aggregation units (AU) which are plotted. Approximately 8 AU corresponds to 1 Ohm. Aggregation measured with Multiplate® is quantified as AU and area under the curve (AUC) of aggregation units (AU \* min). Multiplate® displays and documents aggregation tracings providing a qualitative assessment of platelet function; 2. PCRus: will be determined by the IMMULITE automated analyzer (Immulite, DPC medLAB, Los Angeles, USA). 3. PAI-1 inhibits the serine protease urokinase (uPA) and tissue plasminogen activator (tPA), resulting in the inhibition of fibrinolysis. The elevation of plasma PAI-1 has been described as a prothrombotic factor in arterial and venous thromboembolic disorders. Furthermore, high levels of PAI-1 are associated with an increased incidence of acute coronary syndromes. The determination of plasma PAI-1 will be performed by ELISA. 4. ROTEM: The viscoelastic properties of the clot, such as clot formation (clotting time and clot formation time), clot strength (maximum clot firmness), alpha angle and clot lysis, will be determined using the ROTEM delta device (Instrumentation Laboratory, Bedford, MA, USA). 5. Anti-XA: The Liquid Anti-Xa chromogenic method will be performed with specific calibrators and controls for edoxaban, manufacturer Stago (Diagnostica Stago, France) in automated coagulation equipment STA-R® and STA Compact® (Diagnostica Stago, France). STA® Liquid Anti-Xa are intended for the quantitative determination in plasma of edoxaban, measuring its direct anti-Xa activity in a competitiveness study. Edoxaban levels are given in ng/mL. The detection limit on the STA-R® and STA Compact® is 20 ng/mL and the linearity range extends up to 400 ng/mL. The test will be performed on platelet poor plasma (PPP). 4\. Sample size Previous publications analyzing platelet aggregation in patients with CAD by Multiplate-TRAP® (Roche) showed a mean platelet reactivity of 102 ± 26 AUC. Assuming that the standard deviation of the difference is the same standard deviation as the mean, and a 20% decrease in platelet aggregability after the use of edoxaban, an alpha error of 0.01 two-tailed (considering the multiplicity adjustment by Bonferroni - see below) and a power of 95%, a sample size of 57 patients was obtained. Based on these calculations and considering possible losses to follow-up (approximately 20%), we propose a sample of 70 patients to be analyzed in this study. 5\. Statistical analysis The results will be presented as number and percentage (categorical variables); continuous variables will be presented as means ± SD (Gaussian distribution) or medians and interquartile values (non-Gaussian distribution). Due to the paired design, the interest groups will not be independent from each other. Because of this, comparisons between them in relation to continuous variables will be made using the Student t test for paired samples, for variables with normal distribution, or the Wilcoxon signed rank test, for non-Gaussian distribution variables. Due to the multiplicity of hypotheses (5 in total), the sample size calculation has already been adjusted by Bonferroni, leading to an overall type 1 error of 5%. Therefore, for each individual comparison (edoxaban + aspirin versus aspirin, edoxaban + clopidogrel versus clopidogrel, etc.), a p\<0.01 will be considered statistically significant. Regarding the tests, the multiplicity adjustment will take into account the Multiplate-TRAP®, while Multiplate-ADP® and Multiplate-Aspi® will be considered exploratory. 6\. Ethical issues: This protocol is in accordance with the recommendations contained in the Declaration of Helsinki and was approved, together with the Informed Consent Form (attached), by the Scientific Committee of InCor and by the Research Ethics Committee of HC/FMUSP (CAAE:43768921.6.0000.0068).